Business
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine,
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the products included in the new studies to be shared. “The data we’re presenting at NSGC demonstrates our ongoing commitment to advancing scientific research aimed at improving patient outcomes and delivering innovative products that provide timely, data-driven, actionable insights to inform more personalized patient care,” said Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics. “We’re excited to share this research with the genetic counseling community and to continue collaborating to help make genetic testing more accessible for all patients.” Myriad’s latest innovations and support services will be on display at booth #317 and through a series of poster presentations throughout the conference. Myriad’s presentation scheduleFriday, Nov. 7, 2025, at 5:15pm PT Poster #CAN103: RNA analysis from residual blood aids the interpretation of Variant of Uncertain Significance (VUS) identified in individuals undergoing hereditary cancer genetic testingPoster #GENT253: Fetal fraction amplification yields sufficient fetal fraction to enable cfDNA screening with a low screen-failure rate between 8-10 weeks gestationPoster #PRE365: Provider & patient uptake of prenatal cfDNA screening at an earlier gestational agePoster #PRE363: Prenatal cell-free DNA screening helps uncover maternal colorectal cancer: a case studyPoster #GENT245: High-throughput, automated detection of FXN repeat expansions using repeat primed PCR followed by capillary electrophoresisPoster #PRE385: From concept to care: the evolution of a genetic screening report through clinical and design collaborationPoster #CAN083: The spectrum of germline hereditary cancer mutations within a laboratory-based research registryPoster #EDU161: Shaping the future: Evolving a field-based laboratory rotation to meet the needs of genetic counseling students...